Holaday makes a biotech comeback at QRxPharma

Several years after walking away from EntreMed, John Holaday is back setting up the U.S. operations of Australia's QRxPharma. Holaday is operating out of an incubator in Rockville, MD, preparing for a late-stage trial for an experimental pain drug. Holaday helped develop the program for the pain therapy, which combined two existing opioids. That kind of combinational approach using existing therapies has proven to be popular and effective. Holaday has established more than half a dozen companies, including a few that went public.

- read the The Washington Post article

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.